Ninety One UK Ltd Makes New Investment in AbbVie Inc. $ABBV

Ninety One UK Ltd purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,850 shares of the company’s stock, valued at approximately $746,000.

Several other large investors have also bought and sold shares of ABBV. Burk Holdings LLC bought a new stake in shares of AbbVie in the 2nd quarter worth $30,000. Merkkuri Wealth Advisors LLC purchased a new stake in shares of AbbVie in the first quarter valued at about $34,000. Marquette Asset Management LLC lifted its position in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Phillip James Consulting Co. bought a new position in shares of AbbVie during the fourth quarter valued at about $36,000. Finally, IMG Wealth Management Inc. lifted its position in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie’s Crohn’s Disease Drug Skyrizi Shows More Positive Results
• Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie’s ABBV-1042 Trial Update
• Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie’s Q3 2026 Earnings: What to Expect
• Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
• Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ABBV shares. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Leerink Partners increased their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. BNP Paribas Exane increased their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Royal Bank Of Canada reissued an “outperform” rating and set a $280.00 target price on shares of AbbVie in a research report on Tuesday. Finally, Citigroup boosted their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $283.07 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The company has a market capitalization of $500.13 billion, a PE ratio of 79.96, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. The business has a fifty day moving average price of $261.95 and a two-hundred day moving average price of $238.90.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.